







an Open Access Journal by MDPI

Prevention, Diagnostic and Antimicrobial Treatment of Periprosthetic Joint Infection—Proven Meets Innovative, Complementary Approaches

Guest Editors:

Prof. Dr. Mustafa Citak

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany

Dr. Jochen Salber

Department of Experimental Surgery, Ruhr-University Bochum, Bochum, Germany

Dr. Osman Çiloğlu

Adana City Training and Research Hospital, Department of Orthopedic and Traumatology, Adana, Turkey

Deadline for manuscript submissions:

30 November 2024

Message from the Guest Editors

Dear Colleagues,

We are thrilled to announce our Special Issue focusing on "Prevention, Diagnostics and Antimicrobial Treatments of Periprosthetic Joint Infections—Proven Meets Innovative, Complementary Approaches". Periprosthetic joint infection (PJI) remains a significant challenge in orthopedic surgery, necessitating comprehensive strategies for prevention, reliable diagnostic methods and effective antimicrobial treatments. Our aim in this collection is to bring together current research findings on proven and novel approaches to the prevention, diagnosis and treatment of PJIs and to combine them with expert knowledge on various aspects of PJI management.

This Special Issue serves as an essential resource for orthopedic surgeons, infectious disease specialists, microbiologists, and healthcare professionals committed to addressing the complexities of periprosthetic joint infections and enhancing patient care.

Prof. Dr. Mustafa Citak Dr. Jochen Salber Dr. Osman Çiloğlu *Guest Editors*







IMPACT FACTOR 4.3





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us